Apixaban Prophylaxis Fails to Reduce Clots in Pediatric ALL
Prophylaxis with apixaban (Eliquis) failed to reduce the rate of venous thromboembolism (VTE) in children with newly diagnosed acute lymphoblastic leukemia or lymphoma, according to results from the phase III randomized PREVAPIX-ALL study. During a median follow-up of 27 days, 12% of patients receiving the direct oral anticoagulant had a composite VTE compared with 18% […]